Pharma

Your Article Summary

See Latest Articles

FDA Approves Genzyme's Synvisc-One for Osteoarthritis of the Knee
Genzyme, 02/27/09

Genzyme Corporation announced that the U.S. Food and Drug Administration has granted marketing approval for Synvisc-One, a product intended for the relief of pain associated with osteoarthritis of the knee. Synvisc-One is the only single-injection viscosupplement approved for the treatment of OA knee pain in the United States. This therapy has the potential to redefine the market for viscosupplementation products by extending the benefits of this therapeutic approach to a broader set of patients and reducing the total cost and burden of multiple injections.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09

Safety concerns slow new drug review and approval processes
Formulary , 12/02/09

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09

 See all of Drug/Product Approvals